Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 40Colorectal Neoplasms 9Adenocarcinoma 8Esophageal Neoplasms 7Carcinoma, Hepatocellular 7Neoplasms 5Colonic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Neoplasm Metastasis 4Rectal Neoplasms 3Liver Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Metastatic Gastric Adenocarcinoma 2Melanoma 2Cholangiocarcinoma 2Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma, Alveolar Soft Part 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms by Site 1Lymphoma, Mantle-Cell 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Liver Diseases 1Head and Neck Neoplasms 1HER2-positive Gastric Cancer 1

Interventions

camrelizumab 2apatinib 2Ramucirumab 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × Ramucirumab × Gastrointestinal × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT02314117 2021-08-26

RAINFALL

Eli Lilly and Company

Phase 3 Completed
645 enrolled 22 charts
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡